Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 12/20 | 0.78 |
| ▸ | TLL1 | O43897 | 3/20 | 0.78 |
| ▸ | TLL2 | Q9Y6L7 | 3/20 | 0.78 |
| ▸ | MMP12 | P39900 | 5/20 | 0.58 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20586992 | 1.00 | BMP1 (0.78) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL20586993 | 1.00 | BMP1 (0.78) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16898134 | 0.97 | BMP1 (0.73) | BMP1TLL1TLL2MMP12 | |
| SCHEMBL21802833 | 0.95 | BMP1 (0.70) | BMP1TLL1TLL2MMP12 | |
| SCHEMBL18241225 | 0.95 | BMP1 (0.70) | BMP1TLL1TLL2MMP12 | |
| SCHEMBL18241227 | 0.95 | BMP1 (0.70) | BMP1TLL1TLL2MMP12 | |
| SCHEMBL18255498 | 0.94 | BMP1 (0.69) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL21498416 | 0.94 | BMP1 (0.68) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL18375782 | 0.94 | BMP1 (0.68) | BMP1TLL1TLL2MMP12C3AR1 | |
| SCHEMBL16898015 | 0.93 | BMP1 (0.67) | BMP1TLL1TLL2MMP12C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-12-20 | — | — | US | disclosed |
| WO-2017006296-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | BMP1 1/4885TLL1 6/4885TLL2 11/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | BMP1 1/4885TLL1 6/4885TLL2 11/4885 |
| US-20180362485-A1 | N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS | BMP1, BMP2, BMPR1A | BMP1 1/4885TLL1 8/4885TLL2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.